These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36109095)

  • 1. Progressive loss of the thyroid tissue integrity visualised by serial CT scans.
    Koyama H; Hattori R; Sagawa H; Tanaka T
    BMJ Case Rep; 2022 Sep; 15(9):. PubMed ID: 36109095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
    Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
    Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis.
    Mosaferi T; Tsai K; Sovich S; Wilhalme H; Kathuria-Prakash N; Praw SS; Drakaki A; Angell TE; Lechner MG
    Thyroid; 2022 May; 32(5):496-504. PubMed ID: 35199588
    [No Abstract]   [Full Text] [Related]  

  • 5. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors.
    Iyer PC; Cabanillas ME; Waguespack SG; Hu MI; Thosani S; Lavis VR; Busaidy NL; Subudhi SK; Diab A; Dadu R
    Thyroid; 2018 Oct; 28(10):1243-1251. PubMed ID: 30132401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab.
    Paragliola RM; Corsello A; Papi G; Melfa E; Urbani A; Pontecorvi A; Corsello SM; Carrozza C
    Thyroid; 2020 Jul; 30(7):1091-1094. PubMed ID: 32122271
    [No Abstract]   [Full Text] [Related]  

  • 8. An Evanishing Thyroid During Immune Checkpoint Inhibitor Therapy.
    Cuzzocrea M; Paone G; Ceriani L; Giovanella L
    Clin Nucl Med; 2022 Mar; 47(3):253-254. PubMed ID: 34690289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
    de Filette J; Jansen Y; Schreuer M; Everaert H; Velkeniers B; Neyns B; Bravenboer B
    J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Destructive thyroiditis followed by hypothyroidism associated with infliximab therapy.
    Ozkan C; Altinova AE; Cerit ET; Yalcin MM; Toruner FB; Akturk M; Cakir N
    Endocr Pract; 2014 Nov; 20(11):e207-10. PubMed ID: 25100375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database.
    Garon-Czmil J; Petitpain N; Rouby F; Sassier M; Babai S; Yelehe-Okouma M; Weryha G; Klein M; Gillet P
    Fundam Clin Pharmacol; 2019 Apr; 33(2):241-249. PubMed ID: 30308083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of thyroid 127I stores measured by X-ray fluorescence in subacute thyroiditis.
    Fragu P; Rougier P; Schlumberger M; Tubiana M
    J Clin Endocrinol Metab; 1982 Jan; 54(1):162-6. PubMed ID: 7054213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: A Variety of Immune-Related Adverse Events Triggered by Immune Checkpoint Inhibitors in a Subject With Malignant Melanoma: Destructive Thyroiditis, Aseptic Meningitis and Isolated ACTH Deficiency.
    Katakura Y; Kimura T; Kusano T; Tatsumi F; Iwamoto Y; Sanada J; Fushimi Y; Shimoda M; Kohara K; Nakanishi S; Kaku K; Mune T; Kaneto H
    Front Endocrinol (Lausanne); 2021; 12():722586. PubMed ID: 34712202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical evaluation of thyroid CT values in various thyroid conditions.
    Kaneko T; Matsumoto M; Fukui K; Hori T; Katayama K
    J Comput Tomogr; 1979 Mar; 3(1):1-4. PubMed ID: 262204
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Eshghi N; Garland LL; Nia E; Betancourt R; Krupinski E; Kuo PH
    J Nucl Med Technol; 2018 Sep; 46(3):260-264. PubMed ID: 29599403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
    Delivanis DA; Gustafson MP; Bornschlegl S; Merten MM; Kottschade L; Withers S; Dietz AB; Ryder M
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2770-2780. PubMed ID: 28609832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
    O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
    Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
    Peiró I; Palmero R; Iglesias P; Díez JJ; Simó-Servat A; Marín JA; Jiménez L; Domingo-Domenech E; Mancho-Fora N; Nadal E; Villabona C
    Endocrine; 2019 Jun; 64(3):605-613. PubMed ID: 30805887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients.
    Kotwal A; Kottschade L; Ryder M
    Thyroid; 2020 Feb; 30(2):177-184. PubMed ID: 31813343
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
    Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
    PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.